SkylineDx and NeraCare enter a strategic partnership to advance precision medicine for early-stage melanoma

Excerpt from the Press Release:

ROTTERDAM, Netherlands and SAN DIEGO, April 20, 2023 /PRNewswire/ — SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, today announced its first non-academic strategic partnership with NeraCare GmbH from Frankfurt, Germany to co-develop a test to help life science companies bring lifesaving melanoma therapies to market.

NeraCare, a leading developer of laboratory tests for personalized survival prediction of melanoma patients, is rising to the forefront of modern clinical trial design with its proteomic test, Immunoprint®. Immunoprint®  identifies patients with early-stage melanoma who are at high-risk of relapse and death. This information is invaluable for pharmaceutical companies as they develop therapies for highly specific subsets of a patient population. Immonoprint® will enable drug innovators to include only those patients for their trial that meet the specified criteria, which will in turn improve trial success, and ultimately shorten the time needed to bring their drug to market.

The agreement includes an exclusive co-development and licensing agreement for Immunoprint®. SkylineDx and NeraCare will work together to accelerate the development of Immunoprint®, while leveraging SkylineDx’s global network, and discovery and validation expertise. The companies will present prospective and archival validation data on the potential impact of Immunoprint® for patient selection at the 2023 European Association of Dermato-Oncology congress.

Click the button below to read the entire Press Release:

Continue Reading The Press Release